Authors
Dirck, A., Diggins, N., Perez, W., Parkins, C., Daily, M. A., Turner, R., Slind, L. E., Nguyen, L. K., Malouli, D., Wu, G., Hancock, M. H., Caposio, P.
Abstract
Human cytomegalovirus (HCMV) establishes latency in CD34+ hematopoietic progenitor cells (HPCs), where reactivation is intimately linked to cellular differentiation. We demonstrate that the Notch signaling pathway, a key regulator of stem cell maintenance and differentiation, functions as a barrier to HCMV reactivation. Two viral gene products, UL8 and miR-UL36, modulate this pathway during reactivation. UL8 promotes degradation of the Notch3 receptor via the endosomal/lysosomal pathway, dependent on two tyrosine-based motifs (Y305/314) in its cytoplasmic tail. A UL8 mutant lacking these motifs fails to degrade Notch3, resulting in sustained Notch signaling and impaired reactivation in vitro and in humanized mice. Similarly, miR-UL36 reduces expression of Notch3 and the Notch transcription factor Recombination Signal Binding Protein For Immunoglobulin Kappa J Region (RBPJ), suppressing Notch signaling. Deletion of miR-UL36 inhibits reactivation, but this defect, like that of the UL8 mutant, can be rescued by pharmacologic Notch inhibition. Thus, HCMV employs multiple gene products to suppress Notch signaling and promote conditions conducive to reactivation. These findings reveal how HCMV manipulates host differentiation pathways to control latency and suggest therapeutic strategies to prevent viral recurrence in immunocompromised patients.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 07 Nov 2025.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 39
- Comments 0